Evaluation of efficacy of mammalian and baculovirus expressed E2 subunit vaccine candidates to bovine viral diarrhoea virus.
Bovine viral diarrhoea virus (BVDV) is a worldwide pathogen of cattle causing a wide spectrum of clinical disease. The major envelope glycoprotein of BVDV, E2, induces the production of neutralising antibodies. In this study we compared the protection afforded to cattle after BVDV challenge by two separate E2 vaccine candidates produced by different heterologous protein expression systems. E2 antigen was expressed using the baculovirus expression system (brE2) and a mammalian cell expression system (mrE2). In the first vaccination study the quantity of recombinant protein expressed by the two systems differed. Vaccination of cattle with a higher dose of brE2 or low dose mrE2 gave comparable protection from viral challenge. Immunised animals showed no pyrexia and reduced leucopaenia which contrasted to the unvaccinated controls. In addition virus shedding from the nasal mucosa was decreased in the vaccinated groups and strong humoral responses were evident post-challenge. However, the efficacy of the brE2 vaccine was greatly diminished when a reduced dose was tested, indicating the importance of assessing the type of expression system used in antigen production.
Thomas
Carole
C
Department of Pathology and Infectious Diseases, Royal Veterinary College, Hawkshead Lane, North Mymms, Hertfordshire, AL9 7TA, UK. cthomas@rvc.ac.uk
Young
Natalie J
NJ
Heaney
Judith
J
Collins
Margaret E
ME
Brownlie
Joe
J
D000818:Animals; D000917:Antibody Formation; D016367:Baculoviridae / Q000378:metabolism*; D001912:Bovine Virus Diarrhea-Mucosal Disease / Q000276:immunology / Q000517:prevention & control*; D002417:Cattle; D002460:Cell Line; D030241:Diarrhea Virus 1, Bovine Viral / Q000276:immunology* / Q000302:isolation & purification; D009305:Nasopharynx / Q000821:virology; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000276:immunology; D022223:Vaccines, Subunit / Q000096:biosynthesis / Q000627:therapeutic use; D014759:Viral Envelope Proteins / Q000096:biosynthesis* / Q000276:immunology; D014765:Viral Vaccines / Q000096:biosynthesis* / Q000627:therapeutic use; D017201:Virus Shedding
D011994:Recombinant Proteins; D022223:Vaccines, Subunit; D014759:Viral Envelope Proteins; D014765:Viral Vaccines